Progression free survival (PFS) of palbociclib, in combination with endocrine therapy, in ER+/HER2- breast cancer patients has been reported in PALOMA-1 [23], PALOMA-2 [24] and PALOMA-3 [25, 26]. This evidence concerns the gene ESR1 and breast carcinoma.